To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Boston Scientific will close Silk ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Canaccord Genuity maintained a Buy rating on Boston Scientific (NYSE:BSX) and increased the stock's price target to $98 from $88. The adjustment follows the successful acquisition of Silk Road ...

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

The prospective, multicenter ROADSTER 3 postapproval trial is evaluating the safety and effectiveness of transcarotid artery re ...

Canaccord raised the firm’s price target on Boston Scientific (BSX) to $98 from $88 and keeps a Buy rating on the shares. The firm ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device ...

This, in turn, should boost the top line in the long term. In June 2024, Boston Scientific initiated the acquisition of Silk Road Medical for $1.16 billion. This acquisition is expected to help ...